Akebia Therapeutics, Inc.

Day range

$0.58 – $0.68

Open

$0.59

Prev close

$0.57

Volume

8.8M

Market cap

$157.09M

Shares out

277.11M

P/E

—

P/S

0.72

P/B

6.31

P/FCF

3.92

ROE

-118.6%

ROA

-8.5%

Debt/Equity

1.98

Div yield

0.00%

As of Oct 23, 2026

• Listing deficiency noticeOct 23, 2026

  On October 21, 2026, Akebia Therapeutics, Inc. received a deficiency letter from Nasdaq notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2).

• Executive officer departureOct 14, 2026

  Nicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics, Inc., notified the Company of his decision to resign his employment with the Company for personal reasons. His resignation will be effective November 6, 2026.

• Clinical trial resultsJun 30, 2026

  Results of the planned interim analysis as of June 1, 2026, the data cutoff date, demonstrated that the trial met the predefined stopping criteria with a win odds of 1.16 (95% confidence interval ('CI') 1.06, 1.28, p=0.0016), establishing non-inferiority and superiority of the primary composite endpoint. The results further demonstrated a statistically significant decrease in hospitalizations with Vafseo versus ESA (1.11 versus 1.23 hospitalizations per patient year, incidence rate ratio of 0.90 (95% CI, 0.824, 0.988).

• Quarterly earningsFeb 26, 2026

  On February 26, 2026, Akebia Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025 and recent business highlights related to the commercial launch of Vafseo® (vadadustat) as well as its pipeline.

• Executive compensation changeJan 30, 2026

  On January 28, 2026, the Company entered into an amended and restated executive severance agreement (the "Amended CEO Executive Severance Agreement") with the Company's President and Chief Executive Officer, John P. Butler. The Amended CEO Executive Severance Agreement was approved by the Board of Directors to better align the severance provisions with market practices...Under the Amended CEO Executive Severance Agreement, if Mr. Butler's employment is terminated by the Company without "cause" or he terminates his employment for "good reason", Mr. Butler will be entitled to receive 12 months of base salary continuation, a lump-sum payment equal to 100% of his annual target bonus for the year of termination, and up to 12 months of reimbursement of COBRA premiums.

Days to cover

3.5

Short interest

22.48M

Avg volume

6.41M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Acute Kidney Injury Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
  positiveGlobeNewswire Inc.· Jun 23, 2026
• Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
  neutralGlobeNewswire Inc.· Feb 19, 2026
• Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
  positiveGlobeNewswire Inc.· Feb 4, 2026
• Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
  positiveBenzinga· Dec 1, 2025
• Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
  positiveGlobeNewswire Inc.· Nov 6, 2025